- Management TeamNews
- Management TeamNews
Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company...
News & events
News & events
- Conferences & Events
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it...
- Scientific publications
Factor Xa direct oral anticoagulants (Fxa-DOACs) require rapid reversal in patients with serious bleeding or prior to urgent surgery.
...- Conferences & Events
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it...
- News
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has...
- News
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
- News
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
- Scientific publications
VMX-C001, a modified form of human zymogen factor X, is being developed to stop or prevent bleeding in patients taking...
- News
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announced it will...
- News
VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment of...